Keyword search (3,172 papers available)


Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study.

Author(s): Pieruccini-Faria F, Black SE, Masellis M, Smith EE, Almeida QJ, Li KZH, Bherer L, Camicioli R, Montero-Odasso M...

INTRODUCTION: Gait impairment is common in neurodegenerative disorders. Specifically, gait variability-the stride-to-stride fluctuations in distance and time-has been associated with neurodegenerat...

Article GUID: 33590967

CCCDTD5 recommendations on early non cognitive markers of dementia: A Canadian consensus.

Author(s): Montero-Odasso M, Pieruccini-Faria F, Ismail Z, Li K, Lim A, Phillips N, Kamkar N, Sarquis-Adamson Y, Speechley M, Theou O, Verghese J, Wall...

Introduction: Cognitive impairment is the hallmark of Alzheimer's disease (AD) and related dementias. However, motor decline has been recently described as a prodromal state that can help to de...

Article GUID: 33094146

Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia.

Author(s): Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith...

Alzheimers Dement. 2020 Jul 29;: Authors: Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP,...

Article GUID: 32725777

Guidelines for Gait Assessments in the Canadian Consortium on Neurodegeneration in Aging (CCNA).

Author(s): Cullen S, Montero-Odasso M, Bherer L, Almeida Q, Fraser S, Muir-Hunter S, Li K, Liu-Ambrose T, McGibbon CA, McIlroy W, Middleton LE, Sarquis...

Can Geriatr J. 2018 Jun;21(2):157-165 Authors: Cullen S, Montero-Odasso M, Bherer L, Almeida Q, Fraser S, Muir-Hunter S, Li K, Liu-Ambrose T, McGibbon CA, McIlroy W, Middleton LE, Sarquis-Adamson ...

Article GUID: 29977431

SYNERGIC TRIAL (SYNchronizing Exercises, Remedies in Gait and Cognition) a multi-Centre randomized controlled double blind trial to improve gait and cognition in mild cognitive impairment.

Author(s): Montero-Odasso M, Almeida QJ, Burhan AM, Camicioli R, Doyon J, Fraser S, Li K, Liu-Ambrose T, Middleton L, Muir-Hunter S, McIlroy W, Morais ...

BMC Geriatr. 2018 04 16;18(1):93 Authors: Montero-Odasso M, Almeida QJ, Burhan AM, Camicioli R, Doyon J, Fraser S, Li K, Liu-Ambrose T, Middleton L, Muir-Hunter S, McIlroy W, Morais JA, Pieruccini...

Article GUID: 29661156

Consensus on Shared Measures of Mobility and Cognition: From the Canadian Consortium on Neurodegeneration in Aging (CCNA).

Author(s): Montero-Odasso M, Almeida QJ, Bherer L, Burhan AM, Camicioli R, Doyon J, Fraser S, Muir-Hunter S, Li KZH, Liu-Ambrose T, McIlroy W, Middleto...

J Gerontol A Biol Sci Med Sci. 2019 May 16;74(6):897-909 Authors: Montero-Odasso M, Almeida QJ, Bherer L, Burhan AM, Camicioli R, Doyon J, Fraser S, Muir-Hunter S, Li KZH, Liu-Ambrose T, McIlroy W...

Article GUID: 30101279


Title:SYNERGIC TRIAL (SYNchronizing Exercises, Remedies in Gait and Cognition) a multi-Centre randomized controlled double blind trial to improve gait and cognition in mild cognitive impairment.
Authors:Montero-Odasso MAlmeida QJBurhan AMCamicioli RDoyon JFraser SLi KLiu-Ambrose TMiddleton LMuir-Hunter SMcIlroy WMorais JAPieruccini-Faria FShoemaker KSpeechley MVasudev AZou GYBerryman NLussier MVanderhaeghe LBherer L
Link:https://www.ncbi.nlm.nih.gov/pubmed/29661156?dopt=Abstract
Category:BMC Geriatr
PMID:29661156
Dept Affiliation: PERFORM
1 Department of Medicine, Division of Geriatric Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Canada. mmontero@uwo.ca.
2 Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Canada. mmontero@uwo.ca.
3 Gait and Brain Lab, Parkwood Institute, Lawson Health Research Institute, London, Canada. mmontero@uwo.ca.
4 Sun Life Financial Movement Disorders Research Centre, Wilfrid Laurier University, Waterloo, Canada.
5 Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada.
6 Geriatric and Cognitive Neurology, University of Alberta, Edmonton, Canada.
7 Functional Neuroimaging Unit, University of Montreal, Montreal, Canada.
8 Department of Psychology-University of Ottawa, Ottawa, Canada.
9 Department of Psychology and PERFORM Centre, Concordia University, Montreal, Canada.
10 Department of Physical Therapy, University of British Columbia, Centre for Hip Health and Mobility, and Djavad Mowafaghian Centre for Brain Health, Vancouver Coastal Research Institute, University of British Columbia, Vancouver, Canada.
11 Department of Kinesiology, University of Waterloo, Waterloo, Canada.
12 School of Physical Therapy, University of Western Ontario, London, Canada.
13 Division of Neurology and Department of Medicine, University of Toronto. Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada.
14 Division of Geriatrics and Centre of Excellence in Aging and Chronic Disease, McGill University, Montreal, Canada.
15 Department of Medicine, Division of Geriatric Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Canada.
16 Gait and Brain Lab, Parkwood Institute, Lawson Health Research Institute, London, Canada.
17 Department of Kinesiology, University of Western Ontario, London, Canada.
18 Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Canada.
19 Department of Psychiatry, Division of Geriatric Psychiatry and Department of Medicine, Division of Clinical Pharmacology, University of Western Ontario, London, Canada.
20 Robarts Clinical Trials Inc, London, Canada.
21 Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montréal, Canada.
22 Department of Sports Studies, Bishop's University, Sherbrooke, Canada.
23 Faculty of Medicine, University of Montreal, Montréal, Canada.
24 St. Joseph's Health Care, London, Canada.
25 Montreal Heart Institute, Research Centre, Montreal, Canada.

Description:

SYNERGIC TRIAL (SYNchronizing Exercises, Remedies in Gait and Cognition) a multi-Centre randomized controlled double blind trial to improve gait and cognition in mild cognitive impairment.

BMC Geriatr. 2018 04 16;18(1):93

Authors: Montero-Odasso M, Almeida QJ, Burhan AM, Camicioli R, Doyon J, Fraser S, Li K, Liu-Ambrose T, Middleton L, Muir-Hunter S, McIlroy W, Morais JA, Pieruccini-Faria F, Shoemaker K, Speechley M, Vasudev A, Zou GY, Berryman N, Lussier M, Vanderhaeghe L, Bherer L

Abstract

BACKGROUND: Physical exercise, cognitive training, and vitamin D are low cost interventions that have the potential to enhance cognitive function and mobility in older adults, especially in pre-dementia states such as Mild Cognitive Impairment (MCI). Aerobic and progressive resistance exercises have benefits to cognitive performance, though evidence is somewhat inconsistent. We postulate that combined aerobic exercise (AE) and progressive resistance training (RT) (combined exercise) will have a better effect on cognition than a balance and toning control (BAT) intervention in older adults with MCI. We also expect that adding cognitive training and vitamin D supplementation to the combined exercise, as a multimodal intervention, will have synergistic efficacy.

METHODS: The SYNERGIC trial (SYNchronizing Exercises, Remedies in GaIt and Cognition) is a multi-site, double-blinded, five-arm, controlled trial that assesses the potential synergic effect of combined AE and RT on cognition and mobility, with and without cognitive training and vitamin D supplementation in older adults with MCI. Two-hundred participants with MCI aged 60 to 85 years old will be randomized to one of five arms, four of which include combined exercise plus combinations of dual-task cognitive training (real vs. sham) and vitamin D supplementation (3?×?10,000 IU/wk. vs. placebo) in a quasi-factorial design, and one arm which receives all control interventions. The primary outcome measure is the ADAS-Cog (13 and plus modalities) measured at baseline and at 6 months of follow-up. Secondary outcomes include neuroimaging, neuro-cognitive performance, gait and mobility performance, and serum biomarkers of inflammation (C reactive protein and interleukin 6), neuroplasticity (brain-derived neurotropic factor), endothelial markers (vascular endothelial growth factor 1), and vitamin D serum levels.

DISCUSSION: The SYNERGIC Trial will establish the efficacy and feasibility of a multimodal intervention to improve cognitive performance and mobility outcomes in MCI. These interventions may contribute to new approaches to stabilize and reverse cognitive-mobility decline in older individuals with MCI.

TRIAL REGISTRATION: Identifier: NCT02808676. https://www.clinicaltrials.gov/ct2/show/NCT02808676 .

PMID: 29661156 [PubMed - indexed for MEDLINE]